{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:14:09Z","timestamp":1778202849775,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,7,31]],"date-time":"2011-07-31T00:00:00Z","timestamp":1312070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Following 1\u2010yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with \u03b2\u2010thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy\u2010eight per cent had dose increases at median of 26\u2003wk, suggesting that 1\u2010yr results may not have reflected full deferasirox efficacy. Extension data are presented here. Deferasirox starting dose was 20\u2003mg\/kg\/d (increases to 30\/40\u2003mg\/kg\/d permitted in the core\/extension, respectively). Efficacy was primarily assessed by absolute change in LIC and serum ferritin. Overall, 231 patients received deferasirox in the extension; 67.4% (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.0001) achieved treatment success. By the end of the extension, 66.2% of patients were receiving doses \u226530\u2003mg\/kg\/d. By the end of the 1\u2010yr extension, mean LIC had decreased by 6.6\u2003\u00b1\u20039.4\u2003mg Fe\/g dw (baseline 19.6\u2003\u00b1\u20039.2; <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001) and median serum ferritin by 929\u2003ng\/mL (baseline 3356; <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001). There was a concomitant improvement in liver function markers (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001). Fewer drug\u2010related adverse events were reported in extension than core study (23.8% vs. 44.3%). Doses \u226530\u2003mg\/kg\/d were generally required because of high transfusional iron intake and high baseline serum ferritin levels, highlighting the importance of administering an adequate dose to achieve net negative iron balance.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2011.01662.x","type":"journal-article","created":{"date-parts":[[2011,6,11]],"date-time":"2011-06-11T14:32:26Z","timestamp":1307802746000},"page":"355-365","source":"Crossref","is-referenced-by-count":29,"title":["Importance of optimal dosing \u226530\u2003mg\/kg\/d during deferasirox treatment: 2.7\u2010yr follow\u2010up from the ESCALATOR study in patients with \u03b2\u2010thalassaemia"],"prefix":"10.1111","volume":"87","author":[{"given":"Ali","family":"Taher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen S.","family":"Elalfy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kusai","family":"Al Zir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahina","family":"Daar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Al Jefri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Kriemler\u2010Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"El\u2010Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Roubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"El\u2010Beshlawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912233412607"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02760702"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050711"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01955263"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80375-5"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014696"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109306"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01228.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0177"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200303-451OC"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.44.235.291"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.45.239.13"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.5.911"},{"key":"e_1_2_6_16_2","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once\u2010daily oral chelating agent, in pediatric patients with \u03b2\u2010thalassemia major","volume":"91","author":"Galanello R","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_17_2","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade\u00ae, ICL670), a once\u2010daily, orally\u2010administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_18_2","unstructured":"EXJADE\u00ae(deferasirox) US Prescribing Information.2011.http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/exjade.pdf."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00985.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1420.1420","article-title":"Deferasirox (Exjade\u00ae), the once\u2010daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5\u2010year follow\u2010up","volume":"112","author":"Vichinsky E","year":"2008","journal-title":"Blood"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.4063.4063","article-title":"Efficacy and safety of deferasirox (Exjade\u00ae) in patients with \u03b2\u2010thalassemia major treated for up to 5\u2003years","volume":"114","author":"Cappellini MD","year":"2009","journal-title":"Blood"},{"issue":"2","key":"e_1_2_6_22_2","article-title":"Growth and development of paediatric patients with beta\u2010thalassaemia treated with deferasirox for up to 5\u2003years","volume":"95","author":"Aydinok Y","year":"2010","journal-title":"Haematologica"},{"key":"e_1_2_6_23_2","article-title":"Deferasirox (Exjade\u00ae) in pediatric patients with \u03b2\u2010thalassemia: update of 4.7\u2010year efficacy and safety from extension studies","volume":"112","author":"Piga A","year":"2008","journal-title":"Blood"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310903"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02298.x"},{"key":"e_1_2_6_26_2","article-title":"Dose dependent reductions in serum transaminases and ferritin levels correlate during long\u2010term therapy with deferasirox (Exjade, ICL670)","author":"Brissot P","year":"2007","journal-title":"Book of Abstracts International BioIron Society"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.03.009"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02108.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.4062.4062","article-title":"Efficacy and safety of deferasirox (Exjade\u00ae) in \u03b2\u2010thalassemia patients with myocardial siderosis: 2\u2010year results from the EPIC cardiac sub\u2010study","volume":"114","author":"Pennell DJ","year":"2009","journal-title":"Blood"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203853"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.116.116","article-title":"Impact of compliance, ferritin and LIC on long\u2010term trends in myocardial T2* with deferasirox","volume":"112","author":"Garbowski M","year":"2008","journal-title":"Blood"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07908.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01662.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2011.01662.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T21:31:30Z","timestamp":1697319090000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01662.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,31]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1600-0609.2011.01662.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01662.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,31]]}}}